ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Abstract Number: 1008

Nationwide Historical Cohort Study on the Primary Prophylactic Effects of Colchicine in Cardiovascular Events
Abstract Number: 1009

Pregnancy Outcomes and Comorbidities Among Individuals with Systemic Lupus Erythematosus: A Nationwide Study Using Publicly Funded Health Insurance Claims Data
Abstract Number: 1010

Confounding by Indication in Observational Studies Investigating Glucocorticoid-Associated Adverse Events in Patients with Rheumatoid Arthritis: A Systematic Literature Review
Abstract Number: 1011

Model-based Evaluation of the Potential Public Health Impact of Expanding Medicare Coverage for Weight Loss Medications for Beneficiaries with Knee Osteoarthritis and Obesity in the US.
Abstract Number: 1012

Racial and Gender Disparities in Gout Clinical Trials
Abstract Number: 1013

All roads lead to Rheum? Modeling scenarios of new patients-to-pediatric rheumatologist ratios in different US states
Abstract Number: 1014

Factors Associated with Fibromyalgia Diagnosis amongst People Meeting Criteria: Results from UK Biobank
Abstract Number: 1015

Refining Administrative Algorithms For Accurate Identification of Patients with Systemic Sclerosis In Trinetx Research Network
Abstract Number: 1016

Association between inflammatory biomarkers and predicted heart failure risk in rheumatoid arthritis
Abstract Number: 1017

Effectiveness of Recombinant Zoster Vaccine in Reducing Herpes Zoster Incidence and All-Cause Mortality Among Rheumatoid Arthritis Patients: A Retrospective Cohort Study of 21,046 Individuals from TriNetX U.S. Collaborative Network
Abstract Number: 1018

Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain
Abstract Number: 1019

Associations Between Mental Health Diagnoses and Acute Care Use Among Individuals with Systemic Lupus Erythematosus in the All of Us Research Program
Abstract Number: 1020

Cohort Study of European Ancestry, Geographic Region, Ambient Ultraviolet Irradiance and the Risk of Developing Polymyalgia Rheumatica among Women
Abstract Number: 1021

Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
Abstract Number: 1022

Abuse in Rheumatic Diseases: Associations with Depression, Disability, and Psychosocial Risk Factors

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].